central pulmonary squamous cell carcinoma
Conditions
Interventions
case series:bronchial artery microsphere embolization combined with apatinib
Sponsors
The Second People's Hospital of Yibin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Pathologically confirmed squamous cell carcinoma of the lung; Imaging showed central lung cancer with at least one measurable lesion (RECIST1.1). No surgery opportunity, clinical stage IV or III B; ECOG score is 0-2; Expected survival =3 months; The patient had previously received the first-line chemotherapy regimen with platinum-containing drugs combined with two drugs, and was failure or lesion progression by imaging evaluation; Routine laboratory examination (blood routine, liver and kidney function, coagulation function, etc.) was not significant abnormal. Subjects volunteered to participate in this study and signed informed consent, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: A history of surgery or radiation therapy; Intractable hypertension beyond the control of drugs;Brain metastasis; Severe abnormal coagulation function; Patients with severe cardiopulmonary dysfunction or inability to lie flat; Other antiangiogenic agents (such as endor, bevacizumab, etc.) were used before enrollment.Pregnant or lactating women;Patients with fertility are unwilling or unable to take effective contraceptive measures; Contraindications specified in the instructions for apatinib; Patients are participating in other clinical trials; During the study, the patients were lost to follow-up and the interventional embolization was unsuccessful. Medical imaging examination showed the progress of the disease, and the researchers considered it inappropriate to continue taking apatinib. Patients with NCI-CTC grade 3 or above, bleeding or other toxic side effects, cannot be tolerated after dose adjustment and symptomatic treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective response rate;Disease control rate;quality of life;hemoptysis;abnormal rate of laboratory test;Incidence of adverse events and serious adverse events; | — |
Countries
China
Contacts
Public ContactZhu Jun
The Second People's Hospital of Yibin
Outcome results
None listed